UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities and Exchange Act of 1934

Date of Report: August 1, 2017
(Date of earliest event reported)

Invitae Corporation
(Exact name of registrant as specified in its charter)

Delaware	001-36847	27-1701898
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. employer identification number)

1400 16th Street, San Francisco, California 94103
(Address of principal executive offices, including zip code)

(415) 374-7782
(Registrant's telephone number, including area code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☒

Item 8.01 Other Events.

Invitae Corporation (the "Company") is filing an investor presentation attached hereto as Exhibit 99.1, which is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Reference is made to the Exhibit Index included with this Current Report on Form 8-K.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 31, 2017

INVITAE CORPORATION

By: /s/ Shelly D. Guyer
Name: Shelly D. Guyer
Title: Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Invitae Corporation Investor Presentation.

Exhibit 99.1

INVITAE:

Genetics from downstream to mainstream

August 2017

INVITAE

CONFIDENTIAL

Safe harbor statement

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's expectations regarding second quarter and expected full-year 2017 results; future uses of the company's cash and its cash burn; the company's belief regarding the success of its business model, business strategy and momentum in its business; the drivers of growth in its business; the benefits and attributes of the company's tests; that research continues to point to the broader utility of genetic information and precision of the company's services; the potential benefits and synergies from the proposed acquisitions; statements relating to the structure, timing, stockholder approval and/or completion of the proposed mergers; the expected closing dates of the proposed transactions; future product offerings and growth potential; and the company's business strategy, including its acquisition growth strategy, and its beliefs regarding the ways in which the proposed acquisitions will contribute to that strategy. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks and uncertainties associated with the parties' ability to satisfy the conditions precedent to the consummation of the proposed transactions, including stockholder approval of and the ability to consummate the proposed mergers, the ability of Invitae to conduct the warrant exchange offer, and the participation by CombiMatrix Series F warrant holders of the 90% minimum participation; the occurrence of any event that could give rise to the termination of the merger agreements; unanticipated difficulties or expenditures relating to the proposed transactions; legal proceedings that may be instituted against the parties following announcement of the proposed transactions; disruptions of current plans and operations caused by the announcement or pendency of the proposed transactions; the risk that expected benefits, synergies and growth prospects resulting from the proposed transactions may not be achieved in a timely manner, or at all; the risk the businesses of CombiMatrix and/or Good Start may not be successfully integrated with the company's business following the respective closings; potential difficulties in employee retention as a result of the announcement and pendency of the proposed transactions; the reaction of customers and potential customers, payers, partners and competitors to the announcement of the proposed mergers; the company's failure to manage growth effectively; the successful closing of the private placement; the company's history of losses; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the company's ability to develop and commercialize new tests and expand into new markets; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; the company's ability to raise additional capital on acceptable terms; risks associated with the company's ability to use rapidly changing genetic data to interpret test results accurately, consistently, and quickly; risks associated with the company's limited experience with respect to acquisitions; the risk that one or both of the contemplated acquisitions will not be completed, will be completed on different terms or will not yield some or all of the intended benefits; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2017. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.

INVITAE

Safe harbor statement (cont'd)

Additional Information about the CombiMatrix Merger and Where to Find It

In connection with the CombiMatrix Merger, the Company and CombiMatrix intend to file relevant materials with the SEC, including (a) a registration statement on Form S-4 that will contain a proxy statement/prospectus for CombiMatrix to solicit stockholder approval of the CombiMatrix Merger and (b) a registration statement on Form S-4 that will contain offer documents for the Company to conduct the Warrant Exchange Offer. Investors and securityholders of the Company and CombiMatrix are urged to read these materials when they become available because they will contain important information about the Company and CombiMatrix as well as the CombiMatrix Merger and the Warrant Exchange Offer. The proxy statement/prospectus and the offering documents and other relevant materials (when they become available), and any other documents filed by the Company or CombiMatrix with the SEC, may be obtained free of charge at the SEC web site at www.sec.gov. In addition, investors and securityholders may obtain free copies of the documents (i) filed with the SEC by the Company, by directing a written request to: Invitae Corporation, 1400 16th Street, San Francisco, California 94103, Attention: Investor Relations or (ii) filed with the SEC by CombiMatrix, by directing a written request to: CombiMatrix Corporation, 310 Goddard, Suite 150, Irvine, California 92618, Attention: Investor Relations. Investors and securityholders are urged to read the proxy statement/prospectus, the offering documents and the other relevant materials when they become available before making any voting or investment decision with respect to the CombiMatrix Merger or the Warrant Exchange Offer.

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities in connection with the Merger shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Participants in the Solicitation

The Company and CombiMatrix and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of CombiMatrix in connection with the CombiMatrix Merger. Information regarding the special interests of these directors and executive officers in the CombiMatrix Merger will be included in the proxy statement/prospectus referred to above. Additional information regarding the Company's directors and executive officers is also included in the Company's Annual Report on Form 10-K for the year ended December 31, 2016 and the proxy statement for the Company's 2017 annual meeting of stockholders. Additional information regarding CombiMatrix's directors and executive officers is also included in CombiMatrix's Annual Report on Form 10-K for the year ended December 31, 2016 and the proxy statement for CombiMatrix's 2017 annual meeting of stockholders. These documents are available free of charge at the SEC's web site (www.sec.gov) and from Investor Relations at the Company or CombiMatrix at the addresses set forth above.

INVITAE

Our mission

Bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people

Core Principles:

Driving down the cost of genetic information will increase its personal and clinical utility	Healthcare professionals are fundamental in ordering and interpreting genetic information	People should own and control their own genetic information	Genetic information is more valuable when shared

INVITAE

Simple model disrupting an industry



INVITAE

It's a huge opportunity: everyone with a genome

BRINGING GENETICS INTO MAINSTREAM MEDICINE TO HELP BILLIONS OF PEOPLE

- Everyone has a unique genome that has a significant impact on their health
- There are over 4,000 medically important genetic tests today – most of which are over-priced and under-utilized
- High-quality, low-priced genetic testing will dramatically increase the total market to everyone with access to healthcare



INVITAE

Building a business designed for the genomic era



INVITAE

Recipe for success: build/partner/buy

- Build industry leading platform that is
  - Cost-effective
  - Scalable
  - Content and feature rich
  - Proven in complex and competitive market
- Identify industry partners that can
  - Increase awareness, utility and utilization of Invitae menu
  - Augment content and capabilities
  - Expand existing market or channels
- Seek select acquisition candidates that can
  - Expand our infrastructure and services capabilities
  - Enhance our position in an existing market or provide an entry point into a new market
  - Offer tests capable of being delivered in a cost-effective, scalable manner
  - Contribute positively to cash flow after 2-3 quarters

INVITAE

Alnylam AstraZeneca

BIOMARIN MyoKardia

PARION SCIENCES

AltaVoice Patient Insights Network CancerGeneConnect

CombiMatrix* GoodStart Genetics*

INVITAE

*Pending acquisitions, subject to closing conditions.

Winning the race to scale: unparalleled advantage

HIGH-QUALITY MEDICAL INTERPRETATION AT SCALE



- Capabilities that are difficult to retrofit into large, incumbent operations
- Technology integration is tough to justify at a smaller scale

INVITAE

Better customer experience wins



- Within 3½ years, Invitae has disrupted competitors and has rapidly taken market share
- When all things are created equal (in terms of quality), building a better product (better menu, turnaround time and pricing) wins

INVITAE

Expanding the market from just answering a discrete diagnostic question. . . .

INDIVIDUAL GENES AND PANELS ANSWER SPECIFIC QUESTIONS

The Invitae Test Catalog

CARDIOLOGY

Brugada syndrome
Hypertrophic cardiomyopathy
Long QT syndrome
Short QT syndrome
Andersen-Tawil syndrome
Timothy syndrome

HEREDITARY CANCER

Hereditary cancer syndromes
Hereditary breast and gynecologic cancers panel
Hereditary gynecologic cancer, high-risk panel
Hereditary breast cancer, extended panel
Hereditary breast cancer, high-risk panel
Hereditary breast cancer, moderate-risk panel
Hereditary breast and ovarian cancer syndrome
Hereditary colon cancer
Hereditary colon cancer, high-risk panel
Hereditary pancreatic cancer
Ataxia-telangiectasia
ATM-related cancer risk
Basal cell nevus syndrome
Bloom syndrome
CHEK2-related cancer risk
Familial adenomatous polyposis
Familial cutaneous melanoma
Familial pancreatic adenocarcinoma
FANCC-related cancer risk
Fanconi anemia
Hereditary diffuse gastric cancer
Hereditary papillary renal cell carcinoma
Juvenile polyposis syndrome
Li-Fraumeni syndrome
Lynch syndrome
Multiple endocrine neoplasia type 1
Multiple endocrine neoplasia type 2
MUTYH-associated polyposis
NBN-related cancer risk
Neurofibromatosis type 1
Nijmegen breakage syndrome
PALB2-related cancer risk
Peutz-Jeghers syndrome
PTEN hamartoma tumor syndrome
Von Hippel-Lindau syndrome

NEUROLOGY

Charcot-Marie-Tooth disease, full panel
Hereditary spastic paraplegia, full panel
Ataxia-telangiectasia
BSCL2-related neurologic disorders
Charcot-Marie-Tooth disease autosomal dominant
Charcot-Marie-Tooth disease autosomal recessive
Charcot-Marie-Tooth disease X-linked
Charcot-Marie-Tooth disease type 1
Charcot-Marie-Tooth disease type 2
Charcot-Marie-Tooth disease type 4
Charcot-Marie-Tooth disease type X
Charcot-Marie-Tooth disease dominant intermediate
Distal hereditary motor neuropathy type V
Early-onset seizures and epilepsy
Familial dysautonomia
Generalized epilepsy with febrile seizures plus
Hereditary neuropathy with liability to pressure palsies
Hereditary spastic paraplegia complicated
Hereditary spastic paraplegia, uncomplicated
L1 syndrome
Laing early-onset distal myopathy
MCT8-specific thyroid hormone cell transporter deficiency
MoCHAP-60 disease
Neurofibromatosis type 1
Pelizaeus-Merzbacher disease
PLP1-related disorders
Pyridoxine-dependent epilepsy
SCN1A-related familial hemiplegic migraine
Troyer syndrome

HEMATOLOGY

Hereditary hemochromatosis
Hereditary thrombophilia
Antithrombin III deficiency
Familial erythrocytosis type 2
Fanconi anemia
Protein C deficiency
Protein S deficiency

PEDIATRIC GENETICS

Ciliopathies, full panel
Noonan spectrum disorders
Asphyxiating thoracic dystrophy
Autosomal dominant polycystic kidney disease type 2
Autosomal recessive polycystic kidney disease
Bardet-Biedl syndrome
Berardinelli-Seip congenital lipodystrophy type 2
Bile acid synthesis defect type 3
Bloom syndrome
Campomelic dysplasia
Canavan disease
Cardio-facio-cutaneous syndrome
CHARGE syndrome
Congenital hepatic fibrosis
Costello syndrome
Cystic fibrosis
FG syndrome
Heterotaxy
Hereditary gingival fibromatosis type 1
Joubert syndrome
Legius syndrome
LEOPARD syndrome
Ligase IV syndrome
Lujan syndrome
McKusick-Kaufman syndrome
Meckel-Gruber syndrome
MORM syndrome
Nephronophthisis
Neurofibromatosis type 1
Nijmegen breakage syndrome
Noonan syndrome
Oral-facial-digital syndrome type I
Primary ciliary dyskinesia
Senior-Loken syndrome
Situs inversus
Tay-Sachs disease



INVITAE

…. to capturing the broad potential of genetics

ONLY A PLATFORM THAT CAPTURES THE BREADTH OF THE MARKET CAN LEAD

PATIENTS
Patients Information Tools & Services:
- State of the art genetic testing laboratory
- Hard to do genes
- Genetic counseling
- Family History
- Risk Assessment

ADVOCACY
Data Aggregation & Sharing:
- Genotypic
- Phenotypic
- Surveys



CLINICIANS
Clinical Grade Genetics:
- Genetic thought leadership
- Medical interpretation at scale
- Clinician consultation services & information tools

BIOPHARMA
Connecting Patients to Studies & Treatments:
- Comprehensive test menu
- Access to patients with symptoms & appropriate genetic profiles
- KOL relationships

Invitae Platform

INVITAE

With targeted therapies on the rise, genetic information accelerates biopharma development

PARTNERING TO EXPAND THE INVITAE NETWORK

- Partnerships structured to
  - Quickly identify eligible patients for treatment
  - Expedite clinical trial enrollment through qualified patient identification
  - Provide subsidized testing to rare disease patients through biopharma collaborations
  - Start to target immuno-oncology drugs (ASCO/Keytruda data sets the stage)
- >100 personalized medicines under development[1]
  - 42% of all compounds and 73% of oncology compounds in the pipeline have the potential to be personalized medicines[2]
- Potential partners reaching out to Invitae seeking assistance





INVITAE

[1,3-4]*Kleiner Perkins; Internet Trends 2017; May 5, 2017*
[2]*Tufts Center for the Study of Drug Development, "Personalized Medicine Gains Traction but Still Faces Multiple Challenges," Impact Report, May/June 2015, Volume 17, Number 3*

Current customer segmentation

BETWEEN 1-2 BILLION PEOPLE IN MODERN HEALTHCARE SYSTEM

- Patients currently getting tested ($3-5 billion market today)[1]
- Patients who have or are directly affected by an inherited disease
- People who could benefit from testing to rule out inherited disease for similar symptoms or are family members of affected individuals
- Otherwise healthy individuals

INVITAE

[1]United Health Center for Health Reform and Modernization: Personalized Medicine: Trends and Prospects for the New Science of Genetic Testing and Molecular Diagnostics. Working paper 7, March 2012

How this works today

Of the up to 10% of the population affected by genetic disease, less than 0.5% receive that information by way of an indication-based screen or test report[1]



- Testing remains largely "event based" with patients accessing the market through discreet entry points
- Report generally remains isolated from patient's broader healthcare and long-term health decisions

INVITAE

[1]Global Genes. "RARE Diseases: Facts and Statistics." Available at https://globalgenes.org/rare-diseases-facts-statistics/.

How this will work in the future

A large portion of the population in modernized healthcare systems will have their genetic information managed on their behalf to improve health outcomes for themselves and their families



- Access to comprehensive genetic information services at all major market entry points
- Individuals can access comprehensive genetic information to inform healthcare decisions throughout their lives

INVITAE

How do we get there?

BECOME THE CONTENT-PRICE LEADER IN FAMILY HEALTH AS WELL AS ADULT & PEDIATRIC GENETICS



INVITAE

The time is right: industry is ripe for consolidation



INVITAE

GoodStart Genetics Pending acquisition*

ENTER PERINATAL MARKET WITH STRONG NGS OFFERING IN IVF



INVITAE

*Good Start Genetics is a pending acquisition, but several conditions to a closing must be met. It is possible Good Start Genetics will not become part of Invitae's business.

GoodStart Genetics Strategic rationale

Carrier screening

- First entry point into the broader Perinatal market by way of carrier and PGS/D capabilities in the IVF sector
- Strong relationships with clinicians, seamless customer experience, solid customer workflow tools

PGS/D

- Bolsters Invitae's sales force with the addition of commercial team members covering ~500 IVF clinics nationally
- Similar NGS-based infrastructure that scales effectively with Invitae's additional capabilities and volume
- Strong reimbursement: >130M lives under contract or in credentialing as of Q1 17

INVITAE

Pending acquisition*

EXPAND INTO PRENATAL, MISCARRIAGE & PEDIATRIC TESTING



*CombiMatrix is a pending acquisition, but several conditions to a closing must be met including approval by CombiMatrix stockholders at a public company stockholders meeting and the successful completion of an exchange offer for publicly traded CombiMatrix warrants. It is possible CombiMatrix will not become part of Invitae's business.

Strategic rationale

Fertility & perinatal health

- Adding team with cytogenic expertise, commercial presence and track record of building share against legacy providers
- Adding more prenatal sample types and products of conception

Prenatal testing

- Accelerates conversion from chromosomal microarray (CMA) to next generation sequencing (NGS) testing for perinatal and pediatric primary diagnostic testing
- Trusted provider of miscarriage analysis, historically covered by third-party payers

Neonatal testing

- Bolsters sales force with the addition of commercial team experienced in the perinatal space

INVITAE + GoodStart Genetics* + CombiMatrix*

ACCELERATING INVITAE'S ENTRY INTO FAMILY HEALTH AND PLANNING



One platform
delivering diagnostic-quality genetic information
to inform healthcare decisions
throughout life

INVITAE

*Good Start Genetics and CombiMatrix are pending acquisitions which are subject to closing conditions, and it is possible one or both may not become part of Invitae's business.

Simplifying multiple call points with a consolidated menu: one company, one platform, one sales force

BRINGING GENETIC INFORMATION TO MAINSTREAM MEDICINE



INVITAE


FINANCIALS
INVITAE

Momentum accelerating in 2Q17

- Business success underscored by 2Q17 results*
  - Robust sample volume growth: 30,474, +17% Q/Q
  - Significant Ramp in Revenue: $14.3M, +39% Q/Q
- Invitae preliminary 2Q17 results

($ in millions)	2Q16	1Q17	2Q17E*	YoY Growth*	QoQ Growth*
Vol. Accessions	12,761	26,018	30,474	139%	17%
Revenue	$5.6	$10.3	$14.3	157%	39%
COGS	6.5	9.3	10.5	62%	12%
Gross Profit	(0.9)	0.4	3.1	448%	752%
Operating Expenses	23.9	28.3	31.9	33%	13%
Net Loss	(24.8)	(26.9)	(28.6)	(15%)	(6%)
Ending Cash	90.2	101.5	80.4	-	-
Contracted Payers	95MM	187MM	203MM	-	-

- Well positioned to achieve 2017 revenue guidance
  - Full-year revenue of $55M-$65M
- Increasing guidance on volume
  - 120,000-130,000 samples accessioned in 2017

INVITAE

*2Q17 numbers are preliminary.

Financial snapshot of FY 2016 and FY 2017 illustrative ranges

- Illustrative P&L excludes impact of potential revenue and / or cost synergies resulting from contemplated acquisitions

	2016				2017
($ in millions)	INVITAE	GoodStart Genetics	CombiMatrix	INVITAE Combined	INVITAE Illustrative Ranges*
Revenue	**$25.0**	**$22.5**	**$12.9**	**$60.4**	**$90MM - $105MM**
(-) COGS	27.9	12.8	5.8	46.5	$65MM - $70MM
Gross Profit	**($2.8)**	**$9.7**	**$7.1**	**$14.0**	**35% - 45%**
(-) Operating Expenses	97.4	24.7	11.2	133.3	$150MM - $160MM
Operating Income	**($100.2)**	**($15.0)**	**($4.1)**	**($119.3)**	**($100MM) - ($120MM)**
(+) Other Income / (Expense)	(0.1)	(3.1)	(0.0)	(3.2)	-
Net Loss	**($100.3)**	**($18.1)**	**($4.1)**	**($122.5)**	**($115MM) - ($125MM)**

INVITAE

*For illustrative purposes only and not to be considered guidance. There can be no assurances that either the Good Start Genetics acquisition or the CombiMatrix acquisition will occur, or that illustrative 2017 results will be achieved.

GoodStart Genetics Financials

Carrier screening

PGS/D

	FY 2016 Audited	1Q17 Unaudited*
Revenue	**$22.5**	**$4.9**
(-) COGS	12.8	3.5
Gross Profit	**$9.7**	**$1.4**
(-) Operating Expenses	24.7	5.9
Operating Income	**($15.0)**	**($4.5)**
(+) Other Income / (Expense)	(3.1)	(1.2)
Net Loss	**($18.1)**	**($5.7)**

- Launched new sales channel in January pairing Roche's Harmony NIPT with Good Start Genetics' GeneVu carrier screening test to community OB/GYNs
- Recent introduction of on-line cost estimator enabled volume response to competitive pressure on patient co-payments
- Next-gen PGS offering expected to enable aggressive pricing at attractive margins with potential for additional growth in market share

INVITAE

*1Q17 is illustrative only and is combined January, February and March *without* quarterly adjustments.

GoodStart Genetics Terms

Carrier screening

PGS/D

- Total cash and stock of ~$40MM as follows:
  - Stock consideration of up to ~$15.7MM
  - Payment on assumption of ~$6MM in pre-closing and closing-related liabilities and obligations
  - Additional consideration of ~$18.3MM in cash to pay down venture debt

INVITAE

Financials

	FY 2016 Audited*	1Q17 Unaudited*
Revenue	**$12.9**	**$3.8**
(-) COGS	5.8	1.5
Gross Profit	**$7.1**	**$2.3**
(-) Operating Expenses	11.2	2.8
Operating Income	**($4.1)**	**($0.5)**
(+) Other Income / (Expense)	(0.0)	(0.0)
Net Loss	**($4.1)**	**($0.5)**

Fertility & perinatal health

Prenatal testing

Neonatal testing

- Q1 2017 revenues increased 27% compared to Q1 2016, driven by 32% increase in reproductive health segment
- Test volume in Q1 2017 increased 11% compared to Q1 2016
- IVF largely private-pay market, reducing reimbursement risk
- Miscarriage analysis historically covered by third-party payers

*Based on CombiMatrix reported financial results.

Proposed terms

Fertility & perinatal health

Prenatal testing

Neonatal testing

- Total stock consideration of up to $42MM, consisting of:
  - $27MM for 100% of the issued and outstanding common stock of CombiMatrix
  - Up to $6MM to be offered in exchange for certain other outstanding warrants
  - Up to $9MM in incremental stock consideration based on increased CombiMatrix cash balance due to potential warrants not tendered in the exchange offer
- Targeted closing in 4Q17

Strong balance sheet

- Cash, cash equivalents, restricted cash and marketable securities of $80.4MM as of June 30, 2017
- Additional $20MM debt draw down available
- Decline in cash burn
  - $23.4MM in 1Q17
  - $21.1MM in 2Q17
- Private placement: $73.5MM gross proceed
  - 8,647,058 shares
  - $8.50/share
  - Led by existing investors with significant participation from multiple new investors

INVITAE

Invitae: an emerging leader for the genomic era*

PROVIDING GENETIC INFORMATION THROUGH EVERY STAGE OF LIFE

Aiming to consolidate the industry with a best-in-class platform to drive genetic information into mainstream care for everyone in the healthcare system

INVITAE

*Assumes successful acquisition of both Good Start Genetics and CombiMatrix. It is possible neither Good Start Genetics or CombiMatrix will become part of Invitae's business.


INVITAE